Core Viewpoint - The company, Zhejiang Huama Technology Co., Ltd., is actively exploring new applications for polyethylene glycol (PEG) and poly(ethylene oxide) (PEO) in various industries, including lithium batteries and hydrogels, while also announcing a cash dividend distribution plan for shareholders [2][3][4]. Group 1: Company Performance and Financials - As of June 4, 2025, Huama Technology's stock closed at 12.88 yuan, with a slight increase of 0.39% and a trading volume of 58,000 shares, resulting in a transaction amount of 74.6573 million yuan [1]. - The company reported a net profit attributable to shareholders of 397,776,971.79 yuan for the 2024 fiscal year, while the parent company's net profit was -8,511,370.43 yuan [4]. - The company plans to distribute a cash dividend of 0.21 yuan per share, totaling 120,877,680 yuan, with the record date set for June 10, 2025, and the payment date on June 11, 2025 [3][4]. Group 2: Shareholder Information - The cash dividend distribution will be applicable to all shareholders registered by the end of the record date, with specific tax implications for different types of investors, including a 10% withholding tax for qualified foreign institutional investors [3][4]. - The company has conducted a share buyback of 13,092,000 shares, representing 2.2239% of the total share capital, which will not participate in the dividend distribution [4][5]. Group 3: Market Activity - On June 4, 2025, the net outflow of funds from major investors was 549.29 million yuan, while retail investors saw a net inflow of 836.67 million yuan, indicating varied investor sentiment [2][4].

Core Viewpoint - The recent investor communication by Weisheng Pharmaceutical (02561) highlighted the company's strong position in the growth hormone market, focusing on its innovative long-acting growth hormone product and its strategic approach to commercialization [1][2]. Growth Hormone Market Overview - The growth hormone market in China is valued at over 100 billion RMB, primarily driven by out-of-pocket expenses, with approximately two-thirds of the market covered by private hospitals and clinics [1][2]. - The market is expected to grow to 300 billion RMB by 2030, with long-acting formulations projected to dominate the market share [2]. Product Pipeline and Innovation - Weisheng's long-acting growth hormone product is recognized for its superior clinical data and is the only product to achieve favorable results in head-to-head trials against Japanese formulations [3][4]. - The product utilizes a temporary linkage technology that enhances stability and extends the drug's half-life, allowing for weekly injections while maintaining efficacy [4][6]. Competitive Landscape - The competition in the growth hormone sector is relatively mild, with high barriers to entry for long-acting formulations, making Weisheng's product a leader in the market [3][5]. - The current market is dominated by JinSai, which holds about 80% of the market share, primarily due to its established short-acting products [6][7]. Commercialization Strategy - Weisheng plans to leverage its experienced team to accelerate the transition from short-acting to long-acting products, focusing on key pediatric endocrinologists for efficient market penetration [7][8]. - The company has established global partnerships and strategic agreements to expand its market channels and enhance patient services [7][8]. Future Prospects - The company anticipates that its long-acting growth hormone product will receive approval by the second half of 2025, with a significant market potential targeting 100,000 patients to achieve a billion-level market scale [7][8]. - The introduction of supportive national policies aimed at increasing birth rates is expected to expand the target patient population for growth hormone treatments [22]. Additional Product Developments - Weisheng is also developing innovative therapies such as Navepitide for cartilage development disorders and Parotipide for parathyroid hormone deficiency, both of which are expected to generate substantial revenue due to their unique market positions [8][9].